PVP Ventures Ltd

AGM compliance update

• Purpose: Addendum to AGM Notice with compliance certificate under Regulation 45(3) SEBI LODR for name change.
• Certificate: Issued by Practicing Chartered Accountant; to form part of AGM Notice and Explanatory Statement.
• Subject: Item No.5 in AGM Notice concerns proposed change of company name.
• Document inclusion: Certificate will form part of the AGM Notice and Explanatory Statement.
• AGM date/time: 07 September 2026 at 10:00 A.M. IST via VC/OAVM.
• Other contents: FY2025-26 Annual Report and AGM Notice remain unchanged.
• Board note: Chairman & MD Prasad V. Potluri signed the communication.
• Date: 20 August 2026.
• Exchanges: BSE and NSE; Scrip Code 517556.

AGM and book-closure details

• AGM scheduled for 07-09-2026 at 10:00 AM IST via VC/OAVM.
• Book Closure from 01-09-2026 to 07-09-2026 (inclusive).
• Cut-off date for voting: 31-08-2026; voting entitlement determined.
• E-voting window opens 04-09-2026 09:00 AM IST; ends 06-09-2026 05:00 PM IST.
• Security type: Equity shares affected.

AGM and AR access

• 35th AGM scheduled for 7 September 2026 at 10:00 AM IST via VC/OAVM.
• AR for FY2025-26 emailed to shareholders with registered emails as on Aug 14, 2026.
• AR weblink available on BSE corporate filing page.
• Cut-off date for email registration: 31 August 2026.

KYC, demat and communications

• Reminder to update KYC details under SEBI circular for electronic payments.
• Physical holders must update PAN, address, bank details, signature, and nomination.
• Forms ISR-1/2/3 and SH-13/14 available on company or RTA site.
• Shareholders encouraged to receive notices electronically; green initiative.

Name change

• Board proposes changing the company name to Evervie Health Limited.
• Approval from regulators expected; fresh Certificate of Incorporation to follow; existing rights unaffected.

Board appointments

• Saloni Khandelwal and Srivatsan Kalyanasundaram appointed as Independent Directors, effective 15 May 2026.
• Dr. Ellen Feehan named Executive Director & CEO; Dr. Neeraja Nagarajan named Executive Director & COO.

Remuneration and ESOP

• Special resolution proposed to approve Rs 5 crore managerial remuneration for Prasad V. Potluri for FY2026-27.
• PVP ESOP Scheme 2026 approved; up to 2,00,00,000 options; extends to eligible associates/subsidiaries.

acquisitions and investments

• Acquisitions completed: Biohygea Global Private Limited (52%), Optimus Oncology Private Limited (56.01%), 7 Med India Private Limited (33.24%).
• Goodwill from acquisitions: Biohygea 571.91; Optimus 2,136.14; 7 Med 8,132.36.

AGM and governance

• 35th AGM scheduled for 7 September 2026; via VC/OAVM; ordinary business includes adoption of Standalone and Consolidated financials.
• Statutory auditors M/s CNGSN & Associates LLP appointed for five years from AGM; remuneration and related approvals to be finalized.

Regulatory and governance context

• Board reconstitution aligned to SEBI LODR requirements; independent declarations received for new directors.
• Notice includes related party transaction approvals and name-change resolution; governance enhancements emphasized.

Financial snapshot (context)

• Funding activity includes Rs 150 crore NCDs issued to LICHFL increasing leverage; implications for ratios pending.
• Overall strategy emphasizes monetisation of legacy real estate to fund healthcare platform expansion.

AGM Details

• AGM on 07 September 2026 at 10:00 AM IST via VC/OAVM.
• Cut-off date to vote: 31 August 2026.
• Book closure: 01 September to 07 September 2026 (inclusive).
• E-voting: 04 September 2026, 09:00 IST to 06 September 2026, 05:00 PM IST.

Ordinary Resolutions

• Adopt standalone audited financial statements for the year ended 31 March 2026.
• Adopt audited consolidated financial statements for the year ended 31 March 2026.
• Appoint M/s CNGSN & Associates LLP as Statutory Auditors for five years.

Special Resolutions

• Approve material related party transactions for FY2026-27 up to specified thresholds.
• Change name to Evervie Health Limited and amend MOA/AOA.
• Saloni Khandelwal appointed Non-Executive Independent Director for five years.
• Srivatsan Kalyanasundaram appointed Non-Executive Independent Director for five years.
• Ellen Feehan appointed Executive Director and CEO; remuneration as approved.
• Neeraja Nagarajan appointed Executive Director and COO; remuneration as approved.
• Remuneration for Prasad V. Potluri (MD & Chairman) of Rs 5 crore for FY2026-27; related fees.
• PVP ESOP Scheme 2026 approved; up to 2,000,000 options.
• Extend ESOP 2026 to eligible employees of associates/subsidiaries; administration and adjustments authorized.

Auditor Appointment

• Appoint Statutory Auditors for five years; remuneration to be fixed by the Board.

Directors & KMP Appointments

• Ms. Saloni Khandelwal: Non-Executive Independent Director, five-year term (appointed 15 May 2026).
• Mr. Srivatsan Kalyanasundaram: Non-Executive Independent Director, five-year term (appointed 15 May 2026).
• Dr. Ellen Feehan: Executive Director and CEO, five-year term (appointed 15 May 2026).
• Dr. Neeraja Nagarajan: Executive Director and COO, five-year term (appointed 1 July 2026).

Employee Stock Option Scheme (ESOP) Details

• ESOP Scheme 2026 to be administered by Nomination and Remuneration Committee.
• Options may be issued to employees and certain directors; vesting subject to performance and tenure.
• Exercise price not below face value; exercise period up to 10 years from vesting.

Material Related Party Transactions

• RPTs with defined related parties proposed; terms include goods/services, leasing, loans, and guarantees.
• Transactions subject to arm’s length pricing and annual Audit Committee reviews.

Voting Status

• Voting results are not disclosed in this filing.

Resignation: Kushal Kumar (NED)

• Resigned as Non-Executive Independent Director, effective as per resignation letter, due to personal commitments.

Resignation: Dileep Badey (Executive Director)

• Resigned as Executive Director, effective as per resignation letter, due to personal reasons.

Meeting Details

• Date: 14 August 2026; Time not disclosed; held via VC/OVAM.

Key Agenda Items

• To consider and approve unaudited standalone and consolidated financial results for quarter ended 30 June 2026.

Other Notes

• Trading window closed 01 July 2026 until 48 hours after unaudited results for quarter ended 30 June 2026.

Trading volume clarification

• Clarification to BSE on significant increase in trading volume of PVP Ventures shares.
• Company states it has complied with SEBI LODR disclosure requirements.
• There is no undisclosed material information or impending announcement per company knowledge.
• The volume rise is market-driven, due to normal market operations and investor activity.
• No company action or communication is implicated; governance and disclosure standards remain intact.